SAN FRANCISCO, November 3rd, 2014 – Levin Simes LLP announced that an agreement in principle has been reached to settle claims related to defective recalled Stryker Rejuvenate and Stryker ABG II hip implants sold by Stryker Orthopaedics, a subsidiary of Johnson and Johnson. These include claims of people represented by Levin Simes and other law firms. Stryker Orthopaedics will pay “at least $1.43 billion” for resolution of those claims in the Stryker settlement, as reported by the Associated Press.
Rachel Abrams of Levin Simes, appointed by Judge Donovan Frank of the U.S. District Court for the District of Minnesota to the Plaintiff Steering Committee of the Stryker Rejuvenate and ABG II Hip Implant Products Liability Litigation, has worked on the Stryker litigation for years to help represent both her clients and those around the country. The result of the Plaintiff Steering Committee’s work allows for the categorization of claimants’ injuries based on proof of implant with a recalled Stryker ABG II or Rejuvenate hip implant, and operative reports showing the device was revised and replaced.
As noted in the media by the Peter J. Sampson, a writer for the newspaper The Record: “The settlement includes a $300,000 “base payment” per hip plus additional payments of up to $550,000 for those who suffered complications such as fractures or infections because of their device failure. Those living with a failed hip, but are unable for medical reasons to have it replaced, are eligible for a $75,000 award”.
Levin Simes, LLP is a national products liability firm in San Francisco, California representing clients in all 50 states who have been injured by defective drugs and medical devices including Stryker Rejuvenate, ABG II, and Accolade hip devices, DePuy ASR and metal on metal hips, Actos, and those who suffered a heart attack or stroke from testosterone replacement therapy including Androgel. The firm is also one of the most successful and well respected Mesothelioma and asbestos trial practices in the United States.